• Two new contracts with industry partners for 4DMedical imaging technology
• 4DMedical technology highlighted during Congressional Testimony on VA Healthcare Modernization
• Collaborations underscore 4DMedical's growing reputation as an industry partner for advancing respiratory care

4DMedical Limited (ASX:4DX), a respiratory imaging technology company, has announced that it has been selected by two separate industry partners to provide its ground-breaking lung imaging technology to support bringing new lung disease therapies to market. The company is also pleased to have been referenced by Philips in Congressional Testimony on VA Healthcare Modernization. 4DMedical has been selected by SMS Biotech, a San Diego based biotech company, to provide its unique suite of software tools capable of providing both structural and functional analysis of the lungs, including CT:VQ™ perfusion assessment. This technology will play a critical role in SMS Biotech's clinical trial to assess the impact of their stem cell therapy for the treatment of COPD. Additionally, a medical device developer specializing in respiratory health has also contracted to utilize 4DMedical's technology to enhance their evaluation process for clinical trial candidates. This collaboration highlights the versatility and growing adoption of 4DMedical's technology within the respiratory health sector. Furthermore, 4DMedical's technology was highlighted by Philips in Congressional Testimony on VA Healthcare Modernization, where it was recognized for its ability to aid clinicians in the diagnosis of respiratory conditions, particularly for veterans, and its potential to reduce costs and expedite treatment.